Pemetrexed - Generic Drug Details

What are the generic sources for pemetrexed and what is the scope of freedom to operate?

Pemetrexed is the generic ingredient in six branded drugs marketed by Actavis, Eagle Pharms, Avyxa Holdings, Lilly, Accord Hlthcare, Amneal, Apotex, Baxter Hlthcare Corp, Biocon Pharma, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hetero Labs Ltd Vi, Hospira, Jiangsu Hansoh Pharm, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Prinston Inc, Qilu Pharm Hainan, Reliance Life, Zydus Pharms, Shilpa, and Sandoz, and is included in twenty-nine NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pemetrexed has seven patent family members in five countries.

There are twenty-nine drug master file entries for pemetrexed. Two suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for pemetrexed

International Patents:	7
US Patents:	4
Tradenames:	6
Applicants:	24
NDAs:	29
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	1,107
Patent Applications:	4,753
Drug Prices:	Drug price trends for pemetrexed
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for pemetrexed
What excipients (inactive ingredients) are in pemetrexed?	pemetrexed excipients list
DailyMed Link:	pemetrexed at DailyMed

See drug prices for pemetrexed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for pemetrexed

Constraining patent/regulatory exclusivity:

9,604,990

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for pemetrexed

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Intergroupe Francophone de Cancerologie Thoracique	PHASE2
Regeneron Pharmaceuticals	PHASE2
Tang-Du Hospital	PHASE1

See all pemetrexed clinical trials

Generic filers with tentative approvals for PEMETREXED

Applicant	Application No.	Strength	Dosage Form
		500MG	INJECTABLE;INJECTION
		100MG	INJECTABLE;INJECTION
		1G	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for pemetrexed

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for pemetrexed

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for pemetrexed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meitheal	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	215479-003	Dec 13, 2022	AP	RX	No	No
Apotex	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	209851-001	May 25, 2022	AP	RX	No	No
Shilpa	PEMETREXED	pemetrexed disodium	SOLUTION;INTRAVENOUS	215179-001	May 22, 2023		RX	Yes	Yes	11,147,817		Y

EU/EMA Drug Approvals for pemetrexed

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Alimta	pemetrexed	EMEA/H/C/000564Malignant pleural mesotheliomaAlimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.Non-small-cell lung cancerAlimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.	Authorised	no	no	no	2004-09-20
KRKA d.d.	Pemetrexed Krka	pemetrexed	EMEA/H/C/003958Malignant pleural mesotheliomaPemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.	Authorised	yes	no	no	2018-05-22
Menarini International Operations Luxembourg S.A.	Ciambra	pemetrexed	EMEA/H/C/003788Malignant pleural mesothelioma, , Ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,	Authorised	yes	no	no	2015-12-02

International Patents for pemetrexed

Country	Patent Number	Title	Estimated Expiration
Taiwan	201619161	Crystalline forms of pemetrexed diacid and manufacture processes therefor
Canada	2962383	FORMES CRISTALLINES DU DIACIDE DE PEMETREXED ET LEURS PROCEDES DE PRODUCTION (CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR)
Taiwan	I551603

Supplementary Protection Certificates for pemetrexed

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0432677	SPC/GB05/011	United Kingdom		PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
0432677	7/2005	Austria		PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920

Pemetrexed Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Pemetrexed: A Retrospective and Forward-Looking Market Analysis

Pemetrexed, an antifolate antineoplastic agent, has established a significant market presence primarily for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Developed by Eli Lilly and Company, its commercialization under the brand name Alimta has generated substantial revenue, though its market is now subject to generic competition. This analysis examines the historical market performance, the impact of patent expiries, and the projected financial trajectory of pemetrexed, considering evolving treatment landscapes and the competitive environment.

What is the Primary Indication and Mechanism of Action for Pemetrexed?

Pemetrexed is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), whose disease is not amenable to surgical resection or radiation therapy. It is also approved for the treatment of patients with malignant pleural mesothelioma whose disease is not amenable to surgical resection.

The drug functions as a multimodality antifolate agent. It inhibits key enzymes involved in purine and pyrimidine synthesis, essential building blocks for DNA and RNA. Specifically, it inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). By disrupting these metabolic pathways, pemetrexed effectively blocks cancer cell proliferation and survival. Its chemical formula is C20H22N6O6, and it is typically administered intravenously.

What Was the Commercial Trajectory of Alimta (Pemetrexed)?

Alimta, launched in 2004 in the United States, experienced a period of strong sales growth driven by its efficacy in treating NSCLC and mesothelioma. Eli Lilly's effective marketing and the drug's established role in treatment protocols contributed to its success.

• Peak Sales: Alimta achieved peak annual sales exceeding $2.5 billion in the mid-2010s. For example, in 2015, Alimta sales reached approximately $2.8 billion globally. [1]
• Market Penetration: The drug became a cornerstone therapy for first-line and maintenance treatment of advanced NSCLC, particularly in patients with non-squamous histology. Its use in mesothelioma also contributed significantly to its revenue.
• Patent Expiries and Generic Entry: The primary patent for Alimta expired in the United States in 2019. This marked a critical turning point, opening the door for generic manufacturers to enter the market. Similar patent expiries occurred in other major markets, leading to a phased introduction of generic pemetrexed.

How Did Patent Expiries Impact Pemetrexed Sales?

The expiration of Alimta's key patents led to a substantial and predictable decline in its market share and revenue due to the introduction of generic alternatives.

• US Market: Following the patent expiry in the US in 2019, Eli Lilly faced immediate generic competition. This resulted in a rapid erosion of Alimta's market share and a significant drop in sales. By 2020, US sales of Alimta had fallen by over 50% from their peak. [2]
• International Markets: Similar patterns were observed in Europe and other key pharmaceutical markets. The timing of patent expiries varied by region, leading to a staggered but consistent decline in brand-name sales globally.
• Price Erosion: Generic competition inherently drives down drug prices. The average selling price of pemetrexed significantly decreased post-patent expiry as multiple generic manufacturers competed for market access.

What is the Current Market Landscape for Pemetrexed?

The current market for pemetrexed is characterized by a dominant generic presence, with Eli Lilly's branded Alimta holding a reduced market share.

• Generic Dominance: Generic pemetrexed formulations now constitute the majority of the market by volume and increasingly by value due to price competition. Numerous pharmaceutical companies, including Teva, Mylan (now Viatris), Aurobindo, and Sun Pharma, market generic versions of pemetrexed.
• Eli Lilly's Role: Eli Lilly continues to market Alimta, but its revenue contribution from this drug has diminished considerably. The company focuses on newer oncology assets and maintaining market access for its remaining patented products.
• Market Volume: Despite the price erosion, the overall volume of pemetrexed prescribed has remained relatively stable, indicating its continued clinical utility in its approved indications. The demand is sustained by oncologists' familiarity with the drug and its established efficacy.

What are the Key Competitive Factors in the Pemetrexed Market?

Competition in the pemetrexed market is primarily driven by cost, manufacturing capacity, and supply chain reliability.

• Pricing: This is the most significant competitive factor. Generic manufacturers compete aggressively on price to gain market share.
• Supply Chain and Manufacturing: Reliable supply of high-quality pemetrexed active pharmaceutical ingredient (API) and finished dosage forms is crucial. Companies with robust manufacturing capabilities and efficient supply chains have an advantage.
• Formulation and Delivery: While the core API is the same, minor differences in excipients or formulations, or the availability of specific dosage strengths, can play a role. However, the focus remains overwhelmingly on cost-effective generic production.
• Biosimil vs. Generic: Pemetrexed is a small molecule drug, not a biologic. Therefore, it is subject to generic competition, not biosimilar competition, which applies to large molecule drugs.

How is the Pemetrexed Market Evolving?

The evolution of the pemetrexed market is influenced by advancements in oncology treatment paradigms and the ongoing dynamics of generic drug markets.

• Emergence of Targeted Therapies and Immunotherapies: In NSCLC, significant progress has been made with the development of targeted therapies (e.g., EGFR, ALK inhibitors) and immunotherapies (e.g., PD-1/PD-L1 inhibitors). These newer modalities have altered the treatment landscape, potentially reducing the reliance on traditional chemotherapy agents like pemetrexed in certain patient populations, particularly in first-line settings for patients with specific molecular alterations.
• Retained Role in Specific Subgroups: Despite the rise of new therapies, pemetrexed remains a relevant treatment option for specific subgroups of NSCLC patients (e.g., non-squamous histology without targetable mutations) and for mesothelioma, where its efficacy is well-established. It also continues to be used in second-line settings and as maintenance therapy.
• Cost-Effectiveness: In healthcare systems focused on cost containment, generic pemetrexed offers a cost-effective treatment option, particularly in regions with limited access to newer, more expensive therapies.
• Global Market Access: The availability of generic pemetrexed has expanded access to treatment in emerging markets, where affordability is a major determinant of drug utilization.

What is the Projected Financial Trajectory for Pemetrexed?

The financial trajectory for pemetrexed is characterized by a sustained, albeit diminished, revenue stream from generic sales, with the branded Alimta contribution continuing to decline.

• Generic Market Growth: The global generic pemetrexed market is expected to continue growing, driven by increasing demand in emerging economies and the sustained need for cost-effective chemotherapy. This growth will be measured in volume, with revenue growth being more constrained by intense price competition.
• Eli Lilly's Alimta Revenue: Eli Lilly's revenue from Alimta will continue to decrease. While the drug still generates revenue, it is no longer a significant growth driver for the company. Projections indicate a steady decline, with sales expected to fall below $500 million annually in the coming years. [3]
• Overall Market Value: The total market value for pemetrexed (including both branded and generic) has significantly reduced from its peak. The market value is expected to stabilize or grow modestly in the coming years, driven by volume increases in emerging markets, but the overall value will remain substantially lower than during the Alimta patent exclusivity period.
• Factors Influencing Future Revenue:
  • Oncology Treatment Advancements: Further breakthroughs in targeted therapies and immunotherapies could continue to shift treatment paradigms, potentially reducing overall chemotherapy use.
  • Healthcare Policy and Reimbursement: Government policies on drug pricing and reimbursement will influence the accessibility and adoption of both branded and generic pemetrexed.
  • Emerging Market Penetration: The success of generic manufacturers in expanding market penetration in developing countries will be a key factor in sustaining overall market volume.
  • Clinical Practice Guidelines: Updates to clinical practice guidelines by professional organizations will dictate the continued use of pemetrexed in various treatment scenarios.

What is the Competitive Intensity of the Pemetrexed Market?

The competitive intensity of the pemetrexed market is high.

• Number of Competitors: A large number of generic manufacturers are present in the market, leading to significant competition.
• Product Differentiation: There is minimal product differentiation among generic pemetrexed products; they are largely interchangeable.
• Barriers to Entry: While initial R&D for the original drug was high, barriers to entry for generic manufacturers are primarily related to regulatory approval processes, manufacturing capacity, and establishing distribution networks.
• Price Sensitivity: The market is highly price-sensitive due to the nature of generic competition.

Key Takeaways

Pemetrexed, once a blockbuster oncology drug under the brand name Alimta, has transitioned to a mature market dominated by generic competition following patent expiries. While Eli Lilly's Alimta revenue has declined significantly, the overall demand for pemetrexed persists due to its established efficacy in NSCLC and mesothelioma, particularly as a cost-effective option. The market's future trajectory is shaped by the ongoing advancements in oncology that introduce alternative treatment modalities, but generic pemetrexed will likely maintain a stable, albeit lower-value, market presence globally, especially in emerging economies. Competition is fierce, driven by price, and the sustained utility of pemetrexed in specific patient populations ensures its continued, albeit reduced, financial significance.

Frequently Asked Questions

1. What is the primary therapeutic benefit that led to Pemetrexed's success?

Pemetrexed's success stemmed from its broad-spectrum antifolate activity, demonstrating significant efficacy in improving progression-free survival and overall survival for patients with non-small cell lung cancer (NSCLC), particularly those with non-squamous histology, and in malignant pleural mesothelioma.

2. How has the generic entry of Pemetrexed affected its accessibility globally?

The generic entry has dramatically increased the accessibility of pemetrexed globally. Lower prices have made the treatment available to a wider patient population, especially in middle- and low-income countries where the cost of branded medications is prohibitive.

3. Are there any new indications for Pemetrexed currently under investigation?

While pemetrexed has established indications, ongoing research in oncology often explores its potential in combination therapies or for different stages or subtypes of cancer. However, major new indications have not been a primary driver of its recent market dynamics compared to its established uses.

4. What are the main challenges faced by generic pemetrexed manufacturers?

Generic manufacturers face challenges including intense price competition, navigating complex global regulatory approval processes, ensuring consistent API sourcing and quality, and competing for formulary inclusion and physician prescribing habits against a crowded generic market.

5. How does the emergence of immunotherapies impact the future demand for Pemetrexed?

The increasing use of immunotherapies, such as PD-1/PD-L1 inhibitors, as first-line treatments for NSCLC can reduce the reliance on traditional chemotherapy like pemetrexed in specific patient populations. This shift poses a challenge to future demand, although pemetrexed continues to be utilized in specific patient profiles and salvage settings.

Citations

[1] Eli Lilly and Company. (2016). Form 10-K Annual Report for the fiscal year ended December 31, 2015. U.S. Securities and Exchange Commission.

[2] Eli Lilly and Company. (2021). Form 10-K Annual Report for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission.

[3] Grand View Research. (2023). Pemetrexed Market Size, Share & Trends Analysis Report by Type (Brand, Generic), by Indication (Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma), by Region, and Segment Forecasts, 2023 - 2030.